1064 related articles for article (PubMed ID: 29213270)
21. Targeting tumors with nanobodies for cancer imaging and therapy.
Oliveira S; Heukers R; Sornkom J; Kok RJ; van Bergen En Henegouwen PM
J Control Release; 2013 Dec; 172(3):607-17. PubMed ID: 24035975
[TBL] [Abstract][Full Text] [Related]
22. Nanobodies: The "Magic Bullets" in therapeutics, drug delivery and diagnostics.
Mir MA; Mehraj U; Sheikh BA; Hamdani SS
Hum Antibodies; 2020; 28(1):29-51. PubMed ID: 31322555
[TBL] [Abstract][Full Text] [Related]
23. Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.
Romao E; Morales-Yanez F; Hu Y; Crauwels M; De Pauw P; Hassanzadeh GG; Devoogdt N; Ackaert C; Vincke C; Muyldermans S
Curr Pharm Des; 2016; 22(43):6500-6518. PubMed ID: 27669966
[TBL] [Abstract][Full Text] [Related]
24. Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors.
Hambach J; Mann AM; Bannas P; Koch-Nolte F
Front Immunol; 2022; 13():1005800. PubMed ID: 36405759
[TBL] [Abstract][Full Text] [Related]
25. Generation and characterization of nanobodies targeting GPCR.
Zhang S; Fan Z; Liu J
Biophys Rep; 2024 Feb; 10(1):22-30. PubMed ID: 38737476
[TBL] [Abstract][Full Text] [Related]
26. Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.
Bobkov V; Zarca AM; Van Hout A; Arimont M; Doijen J; Bialkowska M; Toffoli E; Klarenbeek A; van der Woning B; van der Vliet HJ; Van Loy T; de Haard H; Schols D; Heukers R; Smit MJ
Biochem Pharmacol; 2018 Dec; 158():413-424. PubMed ID: 30342023
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
28. Development of a Recombinant Monospecific Anti-PLGF Bivalent Nanobody and Evaluation of it in Angiogenesis Modulation.
Nikooharf A; Arezumand R; Mansouri K; Khoshi AH; Namdar Ahmadabad H
Mol Biotechnol; 2020 Dec; 62(11-12):580-588. PubMed ID: 32975735
[TBL] [Abstract][Full Text] [Related]
29. Nanobodies: from structure to applications in non-injectable and bispecific biotherapeutic development.
Li B; Qin X; Mi LZ
Nanoscale; 2022 May; 14(19):7110-7122. PubMed ID: 35535618
[TBL] [Abstract][Full Text] [Related]
30. NanoBERTa-ASP: predicting nanobody paratope based on a pretrained RoBERTa model.
Li S; Meng X; Li R; Huang B; Wang X
BMC Bioinformatics; 2024 Mar; 25(1):122. PubMed ID: 38515052
[TBL] [Abstract][Full Text] [Related]
31. Nanobodies as versatile tools: A focus on targeted tumor therapy, tumor imaging and diagnostics.
Al-Baradie RS
Hum Antibodies; 2020; 28(4):259-272. PubMed ID: 32831197
[TBL] [Abstract][Full Text] [Related]
32. Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors.
Eichhoff AM; Börner K; Albrecht B; Schäfer W; Baum N; Haag F; Körbelin J; Trepel M; Braren I; Grimm D; Adriouch S; Koch-Nolte F
Mol Ther Methods Clin Dev; 2019 Dec; 15():211-220. PubMed ID: 31687421
[TBL] [Abstract][Full Text] [Related]
33. Nanobodies that Neutralize HIV.
Weiss RA; Verrips CT
Vaccines (Basel); 2019 Jul; 7(3):. PubMed ID: 31370301
[TBL] [Abstract][Full Text] [Related]
34. Nanobody-based cancer therapy of solid tumors.
Kijanka M; Dorresteijn B; Oliveira S; van Bergen en Henegouwen PM
Nanomedicine (Lond); 2015 Jan; 10(1):161-74. PubMed ID: 25597775
[TBL] [Abstract][Full Text] [Related]
35. Generation, expression and utilization of single-domain antibodies for in vivo protein localization and manipulation in sea urchin embryos.
Schrankel CS; Gökirmak T; Lee CW; Chang G; Hamdoun A
Methods Cell Biol; 2019; 151():353-376. PubMed ID: 30948018
[TBL] [Abstract][Full Text] [Related]
36. Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor.
Kazemi-Lomedasht F; Behdani M; Habibi-Anbouhi M; Shahbazzadeh D
Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):167-71. PubMed ID: 27167350
[TBL] [Abstract][Full Text] [Related]
37. [Application of nanobody in cancer treatment].
Wu Y; Hao X; Li M
Sheng Wu Gong Cheng Xue Bao; 2017 Jul; 33(7):1085-1090. PubMed ID: 28869728
[TBL] [Abstract][Full Text] [Related]
38. Structural Basis of Epitope Recognition by Heavy-Chain Camelid Antibodies.
Zavrtanik U; Lukan J; Loris R; Lah J; Hadži S
J Mol Biol; 2018 Oct; 430(21):4369-4386. PubMed ID: 30205092
[TBL] [Abstract][Full Text] [Related]
39. Isolation and optimization of camelid single-domain antibodies: Dirk Saerens' work on nanobodies.
Saerens D
World J Biol Chem; 2010 Jul; 1(7):235-8. PubMed ID: 21537479
[TBL] [Abstract][Full Text] [Related]
40. Design Principles for Bispecific IgGs, Opportunities and Pitfalls of Artificial Disulfide Bonds.
Vaks L; Litvak-Greenfeld D; Dror S; Shefet-Carasso L; Matatov G; Nahary L; Shapira S; Hakim R; Alroy I; Benhar I
Antibodies (Basel); 2018 Jul; 7(3):. PubMed ID: 31544879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
